Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02322775 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
- 20
- Study locations
NCT02322775 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 211 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02322775, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Benralizumab
Study Locations (20)
North Carolina
- Research Site - Charlotte
- Research Site - Monroe
- Research Site - Raleigh
- Research Site - Winston-Salem
California
- Research Site - Los Angeles
- Research Site - Rolling Hills Estates
Florida
- Research Site - Clearwater
- Research Site - Orlando
Ohio
- Research Site - Cincinnati
- Research Site - Grove City
Texas
- Research Site - El Paso
- Research Site - San Antonio
Ontario
- Research Site - Ajax
- Research Site - Burlington
Illinois
- Research Site - Blue Island
New Jersey
- Research Site - Skillman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2015-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02322775
The ClinicalTrials.gov registry entry for NCT02322775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02322775 reports 20 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02322775 about?
NCT02322775 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma". The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease.
What is the current status of trial NCT02322775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2015-02-02. Estimated completion is 2015-10-07.
What conditions does trial NCT02322775 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02322775?
The interventions under investigation include: Placebo (BIOLOGICAL), Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02322775?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02322775 being conducted?
This trial has 20 study locations across California, Florida, Illinois, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.